Management of prostate cancer radiotherapy during the COVID-19 pandemic: A necessary paradigm change

To adapt the management of prostate malignancy in response to the COVID-19 pandemic. In according to the recommendations of the European Association of Urology, we have developed practical additional document on the treatment of prostate cancer. Low-Risk Group Watchful Waiting should be offered to patients >75 years old, with a limited life expectancy and unfit for local treatment. In Active Surveillance (AS) patients re-biopsy, PSA evaluation...